Cyclic combination chemotherapy for metastatic breast cancer.
Forty-four patients with metastatic breast cancer were treated with monthly courses of cyclophosphamide, methotrexate and 5-fluorouracil. Complete remission was achieved in five of the 44 patients (11.4%), partial remission in 17 (38.7%) and stabilization in 19 (43.2%). Progression of the disease was seen in three patients (6.7%). Forty patients are still alive and continue to receive chemotherapy. The main side effects were leukopenia, thrombocytopenia, weakness, nausea and vomiting; all were mild and transient, and were treated symptomatically.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012075:Remission, Spontaneous
D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate